Paratek Presents New Omadacycline (NUZYRA) Data Across Various Serious Infections at IDWeek 2024
核心洞察
Paratek Pharmaceuticals (搜索) is presenting new data on NUZYRA (omadacycline) at IDWeek 2024, highlighting its potential in treating various serious infections.
Interim results from a non-inferiority trial of NUZYRA in bone and joint infections show promising safety data compared to standard-of-care oral antibiotics.
A real-world study assesses NUZYRA's clinical and microbiological outcomes in treating pulmonary Mycobacterium abscessus complex (搜索), a rare pulmonary disease.
Paratek Pharmaceuticals (搜索) is showcasing new research on NUZYRA (omadacycline) at IDWeek 2024, taking place October 16-19 in Los Angeles. The presentations cover a range of serious infections, including bone and joint infections, pulmonary Mycobacterium abscessus complex (搜索), and community-acquired bacterial pneumonia (搜索) (CABP).
Randy Brenner, chief development and regulatory officer of Paratek, stated, “We continue to invest in science as part of our continued commitment to furthering the medical community’s understanding of NUZYRA’s potential utility across a broad range of serious, community-acquired infections, including pulmonary and skin infections.”
Omadacycline for Bone and Joint Infections
Interim safety results from an open-label, non-inferiority, randomized controlled trial evaluating omadacycline versus standard-of-care oral antibiotics for bone and joint infections will be presented. Amy Y. Kang, Pharm.D., BCIDP, will present the poster on Thursday, October 17. This study provides crucial data on the use of omadacycline in treating these challenging infections.
Real-World Outcomes in Pulmonary Mycobacterium Abscessus Complex
Data from a real-world study assessing the clinical and microbiological outcomes of omadacycline in treating pulmonary Mycobacterium abscessus complex (搜索) will be shared by Mohammed Al Musawa, Pharm.D., BCIDP, on Saturday, October 19. This is particularly relevant as Paratek is also evaluating omadacycline in a Phase 2 study for this rare pulmonary disease.
Microbiological Surveillance and Resistance
A five-year microbiologic surveillance study of NUZYRA will be presented by Michael Huband, B.S., on Thursday, October 17. This study analyzes the activity of omadacycline against 35,000 bacterial clinical isolates and resistant organism subsets from patients in the United States between 2019 and 2023. The data offers insights into the evolving resistance patterns and the continued effectiveness of omadacycline.
Additional Presentations
Other presentations include:
- Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin-Structure Infections: Jessica Renee Howard-Anderson, M.D., M.Sc., will present on Thursday, October 17, discussing the development and application of a DOOR endpoint for acute bacterial skin and skin-structure infections.
- Fecal Pharmacokinetics and Metagenomic Changes: Kevin Garey, Pharm.D., will present on Friday, October 18, an evaluation of fecal pharmacokinetics and metagenomic changes following intravenous omadacycline administration to healthy subjects.
- In Vitro Activity Against Neisseria Gonorrhoeae: S.J. Ryan Arends, Ph.D., will present on Friday, October 18, the in vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates.
- Prescribing Practices for Community-Acquired Bacterial Pneumonia (CABP): Tomefa Asempa, Pharm.D., will present on Saturday, October 19, current prescribing practices and guideline concordance for CABP treatment across outpatient and urgent care visits.
These presentations collectively highlight Paratek's ongoing commitment to understanding and expanding the utility of NUZYRA in addressing serious infections.